- Home
- TAOP vs DRMA Comparison
TAOP vs DRMA Comparison
Compare TAOP & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAOP
- DRMA
- Stock Information
- Founded
- TAOP 1993
- DRMA 2014
- Country
- TAOP China
- DRMA United States
- Employees
- TAOP N/A
- DRMA N/A
- Industry
- TAOP Computer Software: Prepackaged Software
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- TAOP Technology
- DRMA Health Care
- Exchange
- TAOP Nasdaq
- DRMA Nasdaq
- Market Cap
- TAOP 2.9M
- DRMA 2.9M
- IPO Year
- TAOP N/A
- DRMA 2021
- Fundamental
- Price
- TAOP $2.62
- DRMA $4.00
- Analyst Decision
- TAOP
- DRMA Strong Buy
- Analyst Count
- TAOP 0
- DRMA 1
- Target Price
- TAOP N/A
- DRMA $10.00
- AVG Volume (30 Days)
- TAOP 350.3K
- DRMA 352.1K
- Earning Date
- TAOP 12-08-2025
- DRMA 11-12-2025
- Dividend Yield
- TAOP N/A
- DRMA N/A
- EPS Growth
- TAOP N/A
- DRMA N/A
- EPS
- TAOP N/A
- DRMA N/A
- Revenue
- TAOP $36,196,786.00
- DRMA N/A
- Revenue This Year
- TAOP N/A
- DRMA N/A
- Revenue Next Year
- TAOP N/A
- DRMA N/A
- P/E Ratio
- TAOP N/A
- DRMA N/A
- Revenue Growth
- TAOP N/A
- DRMA N/A
- 52 Week Low
- TAOP $1.81
- DRMA $3.83
- 52 Week High
- TAOP $24.75
- DRMA $23.70
- Technical
- Relative Strength Index (RSI)
- TAOP 43.84
- DRMA 39.55
- Support Level
- TAOP $1.81
- DRMA $3.93
- Resistance Level
- TAOP $2.80
- DRMA $4.31
- Average True Range (ATR)
- TAOP 0.29
- DRMA 0.29
- MACD
- TAOP -0.01
- DRMA -0.01
- Stochastic Oscillator
- TAOP 50.94
- DRMA 12.60
About TAOP Taoping Inc.
Taoping Inc is a provider of cloud-app technologies for smart city IoT platforms, digital advertising delivery, and other internet-based information distribution systems in China. Its operating segment includes Cloud-based Technology (CBT), Blockchain Technology (BT), and Traditional Information Technology (TIT). It generates maximum revenue from the CBT segment. CBT segment includes cloud-based products and services offered to customers in the private sector including new media, healthcare, education, and residential community management.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.